INBX Stock Recent News
INBX LATEST HEADLINES
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.80 per share a year ago.
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming virtual investor conference: The Evercore ISI 5th Annual HealthCONx Conference Wednesday, November 30 th at 8:45 a.m. Pacific Time The investor conference presentation will be webcast live for at least 60 days following the event and will be accessible through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations.
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Following a rough outing throughout much of this year, biopharmaceutical firm Inhibrx (NASDAQ: INBX ) finally gave stakeholders reason to smile. Earlier today, the company announced it discussed with the Food and Drug Administration (FDA) matters associated with its key therapeutic INBRX-101.
The shares of Inhibrix Inc (NASDAQ:INBX) are soaring today, up 41.1% at $28.48 at last glance, after the company alluded to potentially accelerated U.S. Food & Drug Administration (FDA) approval of its treatment for rare lung disease.
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.